TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31884854

Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg, 150 mg, 300 mg
Number of subjects: 10061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10061
Study: 31124588

Group type: EXPERIMENTAL
Intervention: Oral immunoglobulin supplementation (20 g in milk twice daily for 14 days)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (20 g of a product with similar nutritional value but without immunoglobulins in milk, twice daily for 14 days)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (no supplements)
Number of subjects: 102
Study: 28086991

Group type: EXPERIMENTAL
Intervention: Water aerosol exposure for 1 hour/day (n=33)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (n=26)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Distant site exposure for 1 hour/day (n=32)
Number of subjects: 65
Study: 26004166

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich breakfast (1963 kJ)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Extended morning fasting
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich breakfast
Number of subjects: 35
Study: 23301502

Group type: EXPERIMENTAL
Intervention: Ganciclovir (2.5 mg/kg intravenously)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Valganciclovir (1800 mg orally)
Number of subjects: 6
Study: 21479654

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (low-CHO; 20% CHO, 40% protein, 40% fat)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Moderate-carbohydrate diet (mod-CHO; 55% CHO, 15% protein, 30% fat)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (low-CHO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Moderate-carbohydrate diet (mod-CHO)
Number of subjects: 10
Study: 19339324

Group type: EXPERIMENTAL
Intervention: Recovery Workbook training in addition to usual treatment (N=16)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Treatment as usual (Control group, N=17)
Number of subjects: 33
Study: 19455856

Group type: EXPERIMENTAL
Intervention: Expressive writing about deepest thoughts regarding the exam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral and nonemotional topics writing (Control)
Number of subjects: 0
Study: 16120031

Group type: EXPERIMENTAL
Intervention: Cold forearm
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Warm forearm
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cold fingertip
Number of subjects: 19
Study: 12083533

Group type: EXPERIMENTAL
Intervention: SRP+CHX (scaling and root planing plus chlorhexidine chip)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SRP+CHX
Number of subjects: 20
Study: 9725552

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Terfenadine alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terfenadine with atorvastatin
Number of subjects: 20
Study: 7651649

Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 53
Study: 2528256

Group type: EXPERIMENTAL
Intervention: 20% azelaic acid cream
Number of subjects: 0
Study: 355024

Group type: COMPARATOR
Intervention: Placebo (intramuscular injections)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (tablets)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: No treatment (untreated patients)
Number of subjects: 4
Study: 11369067

Group type: COMPARATOR
Intervention: Conventional computed tomography-based treatment planning (Group A, n=11)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Virtual simulation (Group B, n=12)
Number of subjects: 23
Study: 30519531

Group type: EXPERIMENTAL
Intervention: Therapist-supported internet-based cognitive behavioural therapy (ICBT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 71
Study: 28827103

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bicalutamide 50 mg per day
Number of subjects: 0
Study: 27436788

Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 25275271

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study: 22016505

Group type: EXPERIMENTAL
Intervention: Galectin-3 levels
Number of subjects: 895
Study: 20513067

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiovascular risk factor intervention
Number of subjects: 104
Study: 17673568

Group type: EXPERIMENTAL
Intervention: Testosterone (T) + Resistance training (R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P) + Resistance training (R)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone (T) + No Resistance training (R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P) + No Resistance training (R)
Number of subjects: 0
Study: 15610950

Group type: EXPERIMENTAL
Intervention: ziprasidone (80-120 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: haloperidol (5-20 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 20

Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 20
Study: 12378660

Group type: EXPERIMENTAL
Intervention: Propofol infusion 3-6 mg kg‐1 h‐1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fentanyl infusion 10-30 micrograms kg‐1 h‐1
Number of subjects: 24
Study: 10210379

Group type: EXPERIMENTAL
Intervention: Standard dose of epirubicin (1 mg/ml, 50 mg/50 ml solution)
Number of subjects: 122

Group type: COMPARATOR
Intervention: High dose of epirubicin (2 mg/ml, 100 mg/50 ml solution)
Number of subjects: 122
Study: 7616867

Group type: EXPERIMENTAL
Intervention: Soy flour (n = 28)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Wheat flour (n = 30)
Number of subjects: 58
Study: 2702064

Group type: EXPERIMENTAL
Intervention: Oral intake of 6-mercaptopurine (6-MP) in fasting state
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral intake of 6-mercaptopurine (6-MP) with breakfast
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of fasting state vs. breakfast intake of 6-MP
Number of subjects: 10
Study: 178197

Group type: EXPERIMENTAL
Intervention: 2 mg of glucagon
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg of propantheline bromide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31774299

Group type: EXPERIMENTAL
Intervention: HELP diet with 400 mg/kg Res
Number of subjects: 144

Group type: COMPARATOR
Intervention: HELP diet
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Standard diet with 400 mg/kg Res
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 144
Study: 29906719

Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA)
Number of subjects: 78
Study: 27798024

Group type: EXPERIMENTAL
Intervention: REACH‐HF intervention plus usual care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 50
Study: 24517156

Group type: EXPERIMENTAL
Intervention: Combination therapy (denosumab + teriparatide)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 94

Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 94
Study: 22109255

Group type: EXPERIMENTAL
Intervention: varespladib methyl 500 mg daily
Number of subjects: 6500

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6500
Study: 20629489

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 microg per day)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 17618813

Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula (AVF) at the wrist for chemotherapy administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Chemotherapy through peripheral veins without AVF (historical controls)
Number of subjects: 10
Study: 15755861

Group type: EXPERIMENTAL
Intervention: Estrogen supplementation (2 mg 17beta-estradiol/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (polycose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Estrogen supplementation
Number of subjects: 12
Study: 11682423

Group type: EXPERIMENTAL
Intervention: Epidural ketamine 1 mg/kg combined with 50 microg/kg of morphine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural morphine 50 microg/kg
Number of subjects: 50
Study: 9314448

Group type: EXPERIMENTAL
Intervention: Simulated postexposure boosters intradermally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular vaccine
Number of subjects: 0
Study: 8115073

Group type: EXPERIMENTAL
Intervention: Oral iron therapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dietary counselling
Number of subjects: 43
Study: 2975227

Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31273513

Group type: EXPERIMENTAL
Intervention: Rituximab-based immuno-chemotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 18
Study: 28271382

Group type: EXPERIMENTAL
Intervention: 24-hour shift (24hS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 14-hour night shift (14hS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control day
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: D3 after 14hS
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: D3 after 24hS
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Life-and-death emergencies
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 17
Study: 25162217

Group type: EXPERIMENTAL
Intervention: 400 mg EFV in combination with emtricitabine/tenofovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 mg EFV in combination with emtricitabine/tenofovir
Number of subjects: 0
Study: 23129133

Group type: EXPERIMENTAL
Intervention: DPP lifestyle intervention
Number of subjects: 274
Study: 22372270

Group type: EXPERIMENTAL
Intervention: SmartClip (SC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: In‐Ovation R (IR)
Number of subjects: 40
Study: 19033020

Group type: EXPERIMENTAL
Intervention: 200 microg sodium selenite daily
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: 500 microg sodium selenite daily
Number of subjects: 465

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study: 17066642

Group type: EXPERIMENTAL
Intervention: Rough-surfaced microthreaded neck implants (Oneplant)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Rough-surfaced neck implants (Stage 1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Machined neck implants (Ankylos)
Number of subjects: 68
Study: 12895208

Group type: EXPERIMENTAL
Intervention: Choline bitartrate (50 mg/kg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10875609

Group type: EXPERIMENTAL
Intervention: Protease inhibitor therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV-infected patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV-positive patients at intermediate stage (CD4+ cells >150/microl)
Number of subjects: 0
Study: 9437195

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg daily) and Beta-carotene (20 mg daily)
Number of subjects: 26289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26289
Study: 8133341

Group type: EXPERIMENTAL
Intervention: Cooperative learning strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture reviewing information about diabetes
Number of subjects: 0
Study: 3669070

Group type: EXPERIMENTAL
Intervention: Prompt format (monthly reminders to self-examine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational format (information on breast cancer and breast self-examinations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Demonstration format (demonstrations and practice of examinations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 31542368

Group type: EXPERIMENTAL
Intervention: Intranasal ITN administration
Number of subjects: 143

Group type: COMPARATOR
Intervention: Extranasal ITN administration (control)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Intranasal ITN administration (Study 2)
Number of subjects: 143
Study: 29735394

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Dorzagliatin 75 mg once daily
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Dorzagliatin 100 mg once daily
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Dorzagliatin 50 mg twice daily
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Dorzagliatin 75 mg twice daily
Number of subjects: 258
Study: 27283764

Group type: EXPERIMENTAL
Intervention: Intervention group (assisted in communicating their wishes to their proxy)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 235
Study: 24169009

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 26136

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 26136
Study: 23422767

Group type: EXPERIMENTAL
Intervention: Insulin lispro (7 units) administered subcutaneously
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test with insulin administration
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test without insulin administration
Number of subjects: 100
Study: 20945746

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (1-SEA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (2-SEA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both SE and S3
Number of subjects: 12
Study: 18070192

Group type: EXPERIMENTAL
Intervention: Twinheads (TH) lithotripter
Number of subjects: 240

Group type: COMPARATOR
Intervention: Dornier Lithotripter S (DLS)
Number of subjects: 240
Study: 16014820

Group type: EXPERIMENTAL
Intervention: Written emotional disclosure (3 days of writing about stressful events)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control writing (writing about control topics)
Number of subjects: 50
Study: 12139118

Group type: EXPERIMENTAL
Intervention: 3-4 mmol/L magnesium cold blood cardioplegia (4 degrees C)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 8-10 mmol/L magnesium cold blood cardioplegia (4 degrees C)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 16-18 mmol/L magnesium cold blood cardioplegia (4 degrees C)
Number of subjects: 27
Study: 9823178

Group type: EXPERIMENTAL
Intervention: New transparent dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 0
Study: 7666250

Group type: EXPERIMENTAL
Intervention: Self-selected intake manually calculated by subjects using educational materials
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Self-selected intake recalculated by authors using a computerized database
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dietitian subjects
Number of subjects: 12
Study: 2502938

Group type: EXPERIMENTAL
Intervention: Penicillin VK 500 mg four times daily for five days
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo four times daily for five days
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Penicillin VK 500 mg (compliance considered)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (compliance considered)
Number of subjects: 76
Study: 785197

Group type: EXPERIMENTAL
Intervention: 5‐Fluorouracil plus radiotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: 5‐Fluorouracil plus Imidazole Carboxamide Dimethyl Triazeno plus Vincristine plus Bis‐Chloroethyl Nitrosourea plus radiotherapy
Number of subjects: 70
Study: 7261618

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31961418

Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4 diluted in 0.9% saline
Number of subjects: 775

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 775
Study: 31322735

Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Number of subjects: 280

Group type: COMPARATOR
Intervention: Open liver resection
Number of subjects: 280
Study: 28872381

Group type: EXPERIMENTAL
Intervention: Intermittent sequential pneumatic compression (ISPC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 21
Study: 26275785

Group type: EXPERIMENTAL
Intervention: 3 min break in play
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 8 min break in play
Number of subjects: 141

Group type: COMPARATOR
Intervention: No break
Number of subjects: 141
Study: 24122411

Group type: EXPERIMENTAL
Intervention: Peers encouraging
Number of subjects: 183

Group type: COMPARATOR
Intervention: Peers present
Number of subjects: 183

Group type: COMPARATOR
Intervention: Alone
Number of subjects: 183
Study: 22921332

Group type: EXPERIMENTAL
Intervention: Mobilization with Movement (MWM) and kinesiotaping (KT) techniques
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supervised exercise program
Number of subjects: 20
Study: 18838485

Group type: EXPERIMENTAL
Intervention: Computed virtual chromoendoscopy with the Fujinon intelligent colour enhancement (FICE) system
Number of subjects: 764

Group type: COMPARATOR
Intervention: Standard colonoscopy with targeted indigocarmine chromoscopy (control group)
Number of subjects: 764
Study: 17846141

Group type: EXPERIMENTAL
Intervention: Cephalexin 500 mg orally four times a day for 7 days after incision and drainage
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 15221421

Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5% for 1 week
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo patch for 12 h daily
Number of subjects: 16
Study: 12516939

Group type: EXPERIMENTAL
Intervention: Valaciclovir suspension 10 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Valaciclovir suspension 20 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg tablets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Valaciclovir (both forms)
Number of subjects: 24
Study: 9828736

Group type: EXPERIMENTAL
Intervention: Cisapride 0.2 mg/kg/dose four times daily (n = 18)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 34
Study: 7862849

Group type: EXPERIMENTAL
Intervention: Ephedrine (37.5-75 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 27
Study: 2688064

Group type: EXPERIMENTAL
Intervention: naproxen, 750 mg/day for 1 week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: oxindanac, 600 mg/day for 1 week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: oxindanac
Number of subjects: 16
Study: 1089522

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Carbocromene
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oxyphedrine
Number of subjects: 25
Study: 28728461

Group type: EXPERIMENTAL
Intervention: Audio-visual feedback-on-error
Number of subjects: 11

Group type: COMPARATOR
Intervention: No feedback-on-error
Number of subjects: 11
Study: 27721013

Group type: EXPERIMENTAL
Intervention: High intensity continuous training (HICT; 30 min cycling at 85% VO2max)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sprint interval training (SIT; 6 × 30 s 'all-out' cycling bouts with 4 min recovery periods)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CTRL; no exercise)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training (MICT; 30 min cycling at 65% VO2max)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All exercise intensities (HICT, SIT, MICT)
Number of subjects: 10
Study: 25849467

Group type: EXPERIMENTAL
Intervention: 27-gauge large-bore Septoject XL needle
Number of subjects: 20

Group type: COMPARATOR
Intervention: 27-gauge standard-bore Septoject needle
Number of subjects: 20
Study: 23064293

Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg oral ephedrine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21641868

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus zoledronic acid (20 mg per day + 4 mg every 6 months)
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: Anastrozole plus zoledronic acid (1 mg per day + 4 mg every 6 months)
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Tamoxifen alone (20 mg per day)
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Anastrozole alone (1 mg per day)
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg every 6 months)
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Tamoxifen alone vs Anastrozole alone
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Anastrozole vs Tamoxifen overall survival
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 1803
Study: 19124803

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (fluorouracil-based therapy)
Number of subjects: 20898
Study: 16942532

Group type: EXPERIMENTAL
Intervention: Flexible-dose vardenafil (5-20 mg)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 15254851

Group type: EXPERIMENTAL
Intervention: Valerian/hop extract (2 tablets)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Valerian/hop extract (6 tablets)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Caffeine (200 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11605557

Group type: EXPERIMENTAL
Intervention: Stimulus intensity (dim)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated intensity stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stimulus intensity (bright)
Number of subjects: 0
Study: 9537864

Group type: EXPERIMENTAL
Intervention: Metadoxine (1500 mg/day)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 7521308

Group type: EXPERIMENTAL
Intervention: Ribavirin combined with IFN‐alpha
Number of subjects: 20

Group type: COMPARATOR
Intervention: IFN‐alpha alone
Number of subjects: 20
Study: 2771805

Group type: EXPERIMENTAL
Intervention: Wax matrix potassium chloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microencapsulated potassium chloride
Number of subjects: 0